Lumos Pharma (LUMO) 10-Q 15 May 24 2024 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares	3 Months Ended
	Mar. 31, 2024	May 10, 2024
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2024
Document Transition Report	false
Entity File Number	001-35342
Entity Registrant Name	LUMOS PHARMA, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	42-1491350
Entity Address, Address Line One	4200 Marathon Blvd #200
Entity Address, City or Town	Austin
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	78756
City Area Code	512
Local Phone Number	215-2630
Title of 12(b) Security	Common Stock
Trading Symbol	LUMO
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		8,116,488
Entity Central Index Key	0001126234
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q1
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 23,179	$ 35,078
Short-term investments	0	999
Prepaid expenses and other current assets	4,184	3,748
Other receivables	181	210
Total current assets	27,544	40,035
Non-current assets:
Right-of-use asset	534	603
Total assets	28,078	40,638
Current liabilities:
Accounts payable	569	890
Accrued expenses	3,552	5,858
Current portion of lease liability	293	282
Total current liabilities	4,414	7,030
Long-term liabilities:
Royalty obligation payable to Iowa Economic Development Authority	6,000	6,000
Lease liability	225	303
Total liabilities	10,639	13,333
Commitments and contingencies
Stockholders' equity:
Undesignated preferred stock, $0.01 par value: Authorized shares - 5,000,000 at March 31, 2024 and December 31, 2023; issued and outstanding shares - 0 at March 31, 2024 and December 31, 2023	0	0
Common stock, $0.01 par value: Authorized shares - 75,000,000 at March 31, 2024 and December 31, 2023; issued shares - 8,132,007 and 8,125,728 at March 31, 2024 and December 31, 2023, respectively, and outstanding shares - 8,107,121 and 8,102,555 at March 31, 2024 and December 31, 2023, respectively	81	81
Treasury stock, at cost, 24,886 and 23,173 shares at March 31, 2024 and December 31, 2023, respectively	(201)	(196)
Additional paid-in capital	189,517	188,937
Accumulated deficit	171,958	161,517
Total stockholders' equity	17,439	27,305
Total liabilities and stockholders' equity	$ 28,078	$ 40,638

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Blank check preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Blank check preferred stock, authorized shares (in shares)	5,000,000	5,000,000
Blank check preferred stock, issued shares (in shares)	0	0
Blank check preferred stock, outstanding shares (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized shares (in shares)	75,000,000	75,000,000
Common stock, issued shares (in shares)	8,132,007	8,125,728
Common stock, outstanding shares (in shares)	8,107,121	8,102,555
Treasury stock, shares (in shares)	24,886	23,173

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Royalty revenue	$ 165	$ 691
Total revenues	165	691
Operating expenses:
Research and development	7,248	4,369
General and administrative	3,779	4,357
Total operating expenses	11,027	8,726
Loss from operations	(10,862)	(8,035)
Other income and expense:
Other income, net	263	119
Interest income	158	570
Other income, net	421	689
Net loss	$ (10,441)	$ (7,346)
Net loss per share:
Basic (in dollars per share)	$ (1.29)	$ (0.89)
Diluted (in dollars per share)	$ (1.29)	$ (0.89)
Weighted average number of common shares outstanding:
Basic (in shares)	8,104,905	8,239,941
Diluted (in shares)	8,104,905	8,239,941
Other comprehensive income:
Unrealized gain on short-term investments	$ 0	$ 4
Total comprehensive loss	$ (10,441)	$ (7,342)

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Changes in Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Treasury Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss
Common Stock, balance at beginning of period (shares) at Dec. 31, 2022		8,267,968
Treasury Stock, balance at beginning of period (in shares) at Dec. 31, 2022			15,740
Balance at beginning of period at Dec. 31, 2022	$ 59,584	$ 82	$ (170)	$ 187,164	$ (127,483)	$ (9)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation	586			586
Stock issued upon vesting of restricted stock units (in shares)		4,029
Stock issued upon vesting of restricted stock units	0
Shares surrendered for tax withholding on vested awards (in shares)		(1,007)	(1,007)
Shares surrendered for tax withholding on vested awards	(4)		$ (4)
Repurchases of common stock (in shares)		(87,694)
Repurchases of common stock	(305)	$ (1)		(304)
Other comprehensive income	4					4
Net loss	(7,346)				(7,346)
Common Stock, balance at end of period (shares) at Mar. 31, 2023		8,183,296
Treasury Stock, balance at end of period (in shares) at Mar. 31, 2023			16,747
Balance at end of period at Mar. 31, 2023	$ 52,519	$ 81	$ (174)	187,446	(134,829)	(5)
Common Stock, balance at beginning of period (shares) at Dec. 31, 2023	8,102,555	8,102,555
Treasury Stock, balance at beginning of period (in shares) at Dec. 31, 2023	23,173		23,173
Balance at beginning of period at Dec. 31, 2023	$ 27,305	$ 81	$ (196)	188,937	(161,517)	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation	580			580
Stock issued upon vesting of restricted stock units (in shares)		6,279
Stock issued upon vesting of restricted stock units	0
Shares surrendered for tax withholding on vested awards (in shares)		(1,713)	(1,713)
Shares surrendered for tax withholding on vested awards	(5)		$ (5)
Net loss	$ (10,441)				(10,441)
Common Stock, balance at end of period (shares) at Mar. 31, 2024	8,107,121	8,107,121
Treasury Stock, balance at end of period (in shares) at Mar. 31, 2024	24,886		24,886
Balance at end of period at Mar. 31, 2024	$ 17,439	$ 81	$ (201)	$ 189,517	$ (171,958)	$ 0

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash Flows From Operating Activities
Net loss	$ (10,441)	$ (7,346)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation	580	586
Depreciation and amortization	2	9
Other income, net	(1)	(136)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(437)	(643)
Other receivables	29	22
Accounts payable and accrued expenses	(2,626)	(1,689)
Net cash used in operating activities	(12,894)	(9,197)
Cash Flows From Investing Activities
Purchases of marketable securities	0	(2,463)
Maturities of marketable securities	1,000	0
Net cash provided by (used in) investing activities	1,000	(2,463)
Cash Flows From Financing Activities
Payment for tax withholding on vested awards	(5)	(4)
Repurchases of common stock	0	(305)
Net cash used in financing activities	(5)	(309)
Net decrease in cash and cash equivalents	(11,899)	(11,969)
Cash and cash equivalents at beginning of period	35,078	56,007
Cash and cash equivalents at end of period	$ 23,179	$ 44,038

Description of Business

Description of Business	3 Months Ended
	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	D escription of Business Organization and Nature of Operations Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company. References in this Quarterly Report to “us,” “we,” “our,” the “Company,” or “Lumos” are to Lumos Pharma, Inc. and its wholly-owned subsidiaries. With our principal executive offices located in Austin, Texas and additional executive and administrative offices located in Ames, Iowa, we are engaged in advancing our clinical program and focused on identifying, acquiring, developing, and commercializing novel products and new therapies for people with rare diseases on a global level , for which there is currently a significant unmet need for safe and effective therapies. Our common stock is listed on the Nasdaq Global Market (“Nasdaq”) and trades under the ticker symbol “LUMO.” The Company entered into a business combination (the “Merger”) between the Company, formerly known as NewLink Genetics Corporation (“NewLink”), Cyclone Merger Sub, Inc. (“Merger Sub”), a wholly owned subsidiary of NewLink, and Lumos Pharma, Inc., which has since been renamed “Lumos Pharma Sub, Inc.” (“Private Lumos”). The Merger closed on March 18, 2020, and Merger Sub merged with and into Private Lumos, with Private Lumos surviving as a wholly-owned subsidiary of the Company. After the consummation of the Merger, the combined company has focused its efforts on the development of Private Lumos’ sole product candidate, secretagogue ibutamoren (“LUM-201”), a potential oral therapy for idiopathic pediatric growth hormone deficiency (“PGHD”) and other rare endocrine disorders. Liquidity and Going Concern The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The financial statements also do not reflect any adjustments relating to the recoverability and reclassifications of assets and liabilities that might be necessary if the Company is unable to continue as a going concern. The Company has historically devoted substantially all of its efforts toward research and development and has never earned revenue from commercial sales of its products. Management expects to continue to incur additional substantial losses in the foreseeable future as a result of the Company’s research and development activities. As of March 31, 2024, the Company had approximately $23.2 million of cash and cash equivalents. The Company's accumulated deficit at March 31, 2024 was approximately $172.0 million . Given its current development plans and cash management efforts, the Company anticipates its cash resources will be sufficient to fund operations through the third quarter of 2024. However, based on the Company's current cash forecast and the Company’s dependence on its ability to obtain additional financing to fund its operations in advancing the PGHD program into a Phase 3 trial, the Company concluded that its available cash and cash equivalents as of March 31, 2024 may not be sufficient to fund its operations for at least 12 months from the filing date of this Quarterly Report, and thus substantial doubt exists as to the Company’s ability to continue as a going concern. If the Company is not able to raise additional funding and its available liquidity becomes insufficient to meet the Company’s obligations as they come due, management's plan is to raise additional equity or financing to fund the Company's future operations. There can be no assurances that such financing will be available on terms that are favorable to the Company, or at all. If the Company is unable to raise additional funding to meet its working capital needs in the future, it will be forced to delay or reduce the scope of its research programs, including its LUM-201 Phase 3 trial, and/or limit or cease its operations.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of Lumos and its wholly-owned subsidiaries and have been prepared in accordance with accounting principles generally accepted in the U.S. (“U.S. GAAP”). All significant intercompany accounts and transactions are eliminated in consolidation . Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. GAAP for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments of a normal and recurring nature considered necessary for a fair presentation have been included in the accompanying condensed consolidated financial statements. The results of operations for the interim period are not necessarily indicative of the results that will be realized for the entire fiscal year. These condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements and accompanying notes thereto included in the Company’s 2023 Annual Report filed on Form 10-K with the SEC on March 7, 2024. Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company ’s financial statements and accompanying notes. Significant management estimates that affect the reported amounts of assets and liabilities include stock-based compensation, accruals for clinical trials and deferred tax assets. While we believe that the estimates and assumptions used in preparation of our condensed consolidated financial statements based on our knowledge of current events and actions that we may undertake in the future are appropriate, actual results could differ from those estimates, and any such differences may be material. As of March 31, 2024, the Company’s significant accounting policies are consistent with those discussed in Note 2 - “ Summary of Significant Accounting Policies and Recent Accounting Pronouncements ” of its consolidated financial statements included in the Company’s 2023 Annual Report filed on Form 10-K with the SEC on March 7, 2024. Recent Accounting Pronouncements In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740)—Improvements to Income Tax Disclosures . This ASU requires that reporting entities disclose specific categories in the effective tax rate reconciliation as well as information about income taxes paid. The authoritative guidance is effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the effect of this new guidance on its consolidated financial statements.

License and Asset Purchase Agre

License and Asset Purchase Agreements	3 Months Ended
	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
License and Asset Purchase Agreements	License and Asset Purchase Agreements License and LUM-201 Asset Purchase Agreements In July 2018, the Company entered into an asset purchase agreement (the “APA”) with Ammonett Pharma LLC (“Ammonett”) and acquired substantially all of the assets related to LUM-201, which Ammonett licensed from Merck in October 2013 (the “Lumos Merck Agreement”). The Lumos Merck Agreement, which grants Lumos (as successor in interest to Ammonett) worldwide, exclusive, sublicensable (subject to Merck’s consent in the United States, major European countries and Japan, such consent not to be unreasonably withheld) rights under specified patents and know-how to develop, manufacture and commercialize LUM-201 for any and all indications, excluding Autism Spectrum Disorders as defined in the Fifth Edition of the Diagnostic and Statistical Manual of Mental Disorders. On August 12, 2020, we entered into Amendment No. 1 to the Lumos Merck Agreement with Merck (the “Lumos Merck Agreement Amendment”). Pursuant to the Lumos Merck Agreement Amendment, we obtained from Merck a worldwide, non-exclusive, sublicensable (subject to Merck’s consent in the United States, specified major European countries and Japan, such consent not to be unreasonably withheld) license under the specified patents and know-how that are the subject of our exclusive license to develop, manufacture and commercialize LUM-201 for diagnostic purposes, excluding Autism Spectrum Disorders. Under the APA, the Company paid Ammonett an upfront fee of $3.5 million which was recorded as research and development expense in 2018. The Company may also incur development milestone payments totaling up to $17.0 million for achievement of specified milestones on the first indication that Lumos pursues, of which $2.0 million was paid in March 2024, and up to $14.0 million for achievements of specified milestones on the second indication that Lumos pursues, sales milestone payments totaling up to $55.0 million on worldwide product sales, and royalty payments based on worldwide product sales, as discussed below. Under the Lumos Merck Agreement, Lumos will be required to pay Merck substantial development milestone payments for achievement of specified milestones relating to each of the first and second indications. Total potential development milestone payments are required of up to $14 million for the first indication that Lumos pursues and up to $8.5 million for the second indication that Lumos pursues. Tiered sales milestone payments totaling up to $80.0 million are required on worldwide net product sales up to $1.0 billion, and royalty payments based on product sales are required if product sales are achieved. If product sales are ever achieved, Lumos is required to make royalty payments under both the APA and the Lumos Merck Agreement collectively of 10% to 12% of total annual product net sales, subject to standard reductions for generic erosion. The royalty obligations under the Lumos Merck Agreement are on a product-by-product and country-by-country basis and will last until the later of expiration of the last licensed patent covering the product in such country and expiration of regulatory exclusivity for such product in such country. The royalty obligations under the APA are on a product-by-product and country-by-country basis for the duration of the royalty obligations under the Merck license and thereafter until the expiration of the last patent assigned to Lumos under the APA covering such product in such country. The Lumos Merck Agreement shall continue in force until the expiration of royalty obligations on a country-by-country and product-by-product basis, or unless terminated by Lumos at will by submitting 180 days’ advance written notice to Merck or by either party for the other party’s uncured material breach or specified bankruptcy events. Upon expiry of the royalty obligations the Lumos Merck Agreement converts to a fully paid-up, perpetual non-exclusive license. If the Lumos Merck Agreement is terminated, and upon Merck’s written request, Lumos is obligated to use reasonable and diligent efforts to assign to Merck any sublicenses previously granted by Lumos. License and PRV Asset Purchase Agreements In November 2014, NewLink entered into a worldwide license and collaboration agreement (the “NewLink Merck Agreement”), with Merck, to develop and potentially commercialize its Ebola vaccine rVSV∆G-ZEBOV that it licensed from the Public Health Agency of Canada (“ PHAC ”). rVSV∆G-ZEBOV was also eligible to receive a PRV if approval was granted by the U.S. Food and Drug Administration (the “FDA”), with the Company entitled to 60% and Merck entitled to the remaining 40% of the PRV value obtained through sale, transfer or other disposition of the PRV. On December 20, 2019, Merck announced that the FDA approved its application for ERVEBO® (Ebola Zaire Vaccine, Live) for the prevention of disease caused by Zaire Ebola virus in individuals 18 years of age and older and grant of the PRV. Under the NewLink Merck Agreement, as amended , the Company has earned and has the potential to continue to earn royalties on sales of the vaccine in certain countries. However, we believe that the market for the vaccine will be limited primarily to areas in the developing world that are excluded from royalty payment or where the vaccine is donated or sold at low or no margin, and therefore we do not expect to receive material royalty payments from Merck in the foreseeable future. For the three months ended March 31, 2024 and 2023, the Company recognized revenues of $0.2 million and $0.7 million, respectively, for royalties related to royalty-bearing commercial sales of the vaccine. Additionally, per the terms of the licensing agreement with the PHAC, the Company has an obligation to pay a royalty fee to the PHAC for any royalty amounts earned. For the three months ended March 31, 2024 and 2023, the Company incurred royalty expense of $0.1 million and $0.4 million, respectively, for royalties related to royalty-bearing commercial sales of the vaccine. Royalty expenses are included within general and administrative expenses in the consolidated statements of operations.

Financial Instruments

Financial Instruments	3 Months Ended
	Mar. 31, 2024
Fair Value Disclosures [Abstract]
Financial Instruments	Financial Instruments Fair Value The fair values of the Company’s financial instruments are recorded using a hierarchical disclosure framework based upon the level of subjectivity of the inputs used in measuring assets and liabilities. The three levels are described below: • Level 1: Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date . • Level 2: Inputs other than Level 1 that are directly or indirectly observable, such as quoted prices for similar assets or liabilities and quoted prices in less active markets. • Level 3: Inputs are unobservable for the asset or liability and are developed based on the best information available in the circumstances, which might include the Company’s own data. The following summarizes the valuation of the Company’s financial instruments (in thousands). The tables do not include either cash on hand or assets and liabilities that are measured at historical cost or any basis other than fair value. As of March 31, 2024 Level 1 Level 2 Total Cash equivalents: Money market funds $ 22,553 $ — $ 22,553 Total cash equivalents $ 22,553 $ — $ 22,553 As of December 31, 2023 Level 1 Level 2 Total Cash equivalents: Money market funds $ 34,741 $ — $ 34,741 Total cash equivalents $ 34,741 $ — $ 34,741 Short-term investments: U.S. government and agency securities — 999 999 Total short-term investments $ — $ 999 $ 999 Total $ 34,741 $ 999 $ 35,740 As of March 31, 2024 and December 31, 2023, the Company had no Level 3 assets or liabilities. The Company’s other financial instruments, including cash, receivables and accounts payable, are recorded at amounts that approximate their fair values due to their short maturities. The Company is unable to estimate the fair value of the royalty obligation to Iowa Economic Development Authority based on future product sales, as the timing of payments, if any, is uncertain. Contractual Maturities of Investments As of March 31, 2024, all of the Company's available-for-sale investments were due within one year or less. Available-for-sale Investments The following table summarizes the Company's available-for-sale securities by security type: As of March 31, 2024 Amortized Cost Unrealized Losses Fair Value Cash equivalents: Money market funds $ 22,553 $ — $ 22,553 Total cash equivalents $ 22,553 $ — $ 22,553 As of December 31, 2023 Amortized Cost Unrealized Losses Fair Value Cash equivalents: Money market funds $ 34,741 $ — $ 34,741 Total cash equivalents $ 34,741 $ — $ 34,741 Short-term investments: U.S. government and agency securities 999 — 999 Total short-term investments $ 999 $ — $ 999 Total $ 35,740 $ — $ 35,740 As of March 31, 2024 and December 31, 2023, there were no material unrealized gains associated with the Company’s available-for-sale investments.

Accrued Expenses

Accrued Expenses	3 Months Ended
	Mar. 31, 2024
Payables and Accruals [Abstract]
Accrued Expenses	Accrued Expenses Accrued expenses are comprised of the following (in thousands): March 31, 2024 December 31, 2023 Compensation and related benefits $ 1,752 $ 3,472 Clinical and contract manufacturing expenses 1,388 1,790 Other 412 596 Total accrued expenses $ 3,552 $ 5,858

Stock-Based Compensation and Em

Stock-Based Compensation and Employee Benefit Plans	3 Months Ended
	Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation and Employee Benefit Plans	Stock-Based Compensation and Employee Benefit Plans Stock Options and Performance Stock Options In 2012, Private Lumos adopted the 2012 Equity Incentive Plan (“2012 Plan”), and in 2016 it adopted the 2016 Stock Plan (“2016 Plan” and together with the 2012 Plan, the “Plans”). In connection with the Merger, all outstanding options under the Plans were assumed and such assumed options may be exercised to purchase common stock of the Company after the Merger. Subsequent to the Merger, the Plans were terminated as to future awards . In connection with the Merger, the Company assumed NewLink’s 2009 Equity Incentive Plan which was effective since July 2009 and was subsequently amended on May 9 , 2019 (the “2019 Plan”) . The 2019 Plan has a 10 year term from the Board adoption date of March 22, 2019 and on January 1 of each year through January 1, 2029, in accordance with an “evergreen provision”, a number of shares of common stock in an amount equal to 3% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year or such lesser amount of shares (or no shares) approved by the Board, will be added to the shares reserved under the 2019 Plan. The 2019 Plan provides for the grant of incentive stock options, nonstatutory stock options, restricted stock awards and stock appreciation rights to officers, employees, members of the Board, advisors, and consultants to the Company . As of March 31, 2024, we had 791,018 shares available for grant under the 2019 Plan. 2010 Non-Employee Directors' Stock Award Plan In connection with the Merger , the Company assumed NewLink’s 2010 Non-Employee Directors’ Stock Award Plan (the Directors’ Plan) which was effective on November 10, 2011. As of March 31, 2024, 5,624 shares remain available for grant under the Directors' Plan. 2010 Employee Stock Purchase Plan In connection with the Merger, the Company assumed NewLink’s 2010 Employee Stock Purchase Plan, as amended (the “2010 Purchase Plan”), which was effective on November 10, 2011. As of March 31, 2024, 35,946 shares remain available for issuance under the 2010 Purchase Plan. On July 22, 2021, the Board approved an amendment and restatement of the 2010 Purchase Plan (the “A&R ESPP”), and established a special offering period under the A&R ESPP beginning September 1, 2021 and lasting until June 30, 2023, subject to restart provisions as described within the A&R ESPP. The special offering period under the A&R ESPP was fully contingent upon stockholder approval of the A&R ESPP at the 2022 Annual Meeting of Stockholders. The A&R ESPP provided for an increase in the number of shares reserved for issuance under the A&R ESPP by 60,000 shares. On May 4, 2022, at the 2022 Annual Meeting of Stockholders, the A&R ESPP was approved. On June 30, 2022, December 30, 2022, and June 30, 2023, the restart provision was triggered, resulting in new offering periods. The current offering period is from July 1, 2023 through June 30, 2025. Share-Based Compensation Expense Stock-based compensation expenses included in the Company’s condensed consolidated statements of operations for the three months ended March 31, 2024 and 2023 were (in thousands): Three Months Ended March 31, 2024 2023 Research and development $ 142 $ 157 General and administrative 438 429 Total $ 580 $ 586 As of March 31, 2024, we had unrecognized compensation cost of $2.3 million and the weighted-average period over which it is expected to be recognized is 2.1 years.

Long-Term Debt and Conversion t

Long-Term Debt and Conversion to Royalty Obligation	3 Months Ended
	Mar. 31, 2024
Debt Disclosure [Abstract]
Long-Term Debt and Conversion to Royalty Obligation	Long-Term Debt and Conversion to Royalty Obligation In March 2005, NewLink entered into a $6.0 million forgivable loan agreement with the Iowa Department of Economic Development (the “IDED”). Under the agreement, in the absence of default, there were no principal or interest payments due until the completion date for the project. This loan was converted into a royalty obligation under the terms of a settlement agreement entered into on March 26, 2012 (the “IEDA Agreement”), with the Iowa Economic Development Authority (the “IEDA”), as successor in interest to the IDED. As no payments are expected in the next 12 months, the entire royalty obligation of $6.0 million, which we assumed in connection with the Merger, is classified as a long-term liability as of March 31, 2024.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2024
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes For each of the three months ended March 31, 2024 and 2023, the Company recorded no income tax benefit. The income tax amount for each of the three months ended March 31, 2024 and 2023 differs from the amount that would be expected after applying the statutory U.S. federal income tax rate primarily due to an increase in the valuation allowance. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Due to the uncertainty of the Company’s ability to realize the benefit of the deferred tax assets, the net deferred tax assets are fully offset by a valuation allowance at March 31, 2024. Based on Section 382 ownership change analyses through March 18, 2020, as a result of the Merger, both historical NewLink and Private Lumos experienced Section 382 ownership changes on March 18, 2020. These ownership changes limit our ability to utilize federal net operating loss carryforwards and certain other tax attributes that accrued prior to the respective ownership changes of us and our subsidiaries and may continue to limit our ability to utilize such attributes in the future. Based on subsequent analyses, we did not experience a Section 382 ownership change from March 19, 2020 through December 31, 2022.

Net Loss per Share of Common St

Net Loss per Share of Common Stock	3 Months Ended
	Mar. 31, 2024
Earnings Per Share [Abstract]
Net Loss per Share of Common Stock	Net Loss per Share of Common Stock Basic loss per share is based upon the weighted-average number of shares of common stock outstanding during the period, without consideration of common stock equivalents. Diluted loss per share is based upon the weighted-average number of common shares outstanding during the period plus additional weighted-average potentially dilutive common stock equivalents during the period when the effect is dilutive. The following table presents the computation of basic and diluted loss per share of common stock (in thousands, except share and per share data) and the number of unexercised stock options and restricted stock units, which are common stock equivalents, that have been excluded from the diluted net loss calculation as their effect would have been anti-dilutive for all periods presented. Three Months Ended March 31, 2024 2023 Net loss $ (10,441) $ (7,346) Weighted-average shares outstanding - Basic and diluted 8,104,905 8,239,941 Net loss per share - Basic and diluted $ (1.29) $ (0.89) Anti-dilutive stock options 1,553,359 1,490,884 Anti-dilutive restricted stock units 55,901 76,165 Total anti-dilutive common stock equivalents excluded 1,609,260 1,567,049

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of Lumos and its wholly-owned subsidiaries and have been prepared in accordance with accounting principles generally accepted in the U.S. (“U.S. GAAP”). All significant intercompany accounts and transactions are eliminated in consolidation .
Liquidity and Going Concern/ Basis of Presentation	Liquidity and Going Concern The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The financial statements also do not reflect any adjustments relating to the recoverability and reclassifications of assets and liabilities that might be necessary if the Company is unable to continue as a going concern. The Company has historically devoted substantially all of its efforts toward research and development and has never earned revenue from commercial sales of its products. Management expects to continue to incur additional substantial losses in the foreseeable future as a result of the Company’s research and development activities. As of March 31, 2024, the Company had approximately $23.2 million of cash and cash equivalents. The Company's accumulated deficit at March 31, 2024 was approximately $172.0 million . Given its current development plans and cash management efforts, the Company anticipates its cash resources will be sufficient to fund operations through the third quarter of 2024. However, based on the Company's current cash forecast and the Company’s dependence on its ability to obtain additional financing to fund its operations in advancing the PGHD program into a Phase 3 trial, the Company concluded that its available cash and cash equivalents as of March 31, 2024 may not be sufficient to fund its operations for at least 12 months from the filing date of this Quarterly Report, and thus substantial doubt exists as to the Company’s ability to continue as a going concern. If the Company is not able to raise additional funding and its available liquidity becomes insufficient to meet the Company’s obligations as they come due, management's plan is to raise additional equity or financing to fund the Company's future operations. There can be no assurances that such financing will be available on terms that are favorable to the Company, or at all. If the Company is unable to raise additional funding to meet its working capital needs in the future, it will be forced to delay or reduce the scope of its research programs, including its LUM-201 Phase 3 trial, and/or limit or cease its operations. Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. GAAP for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments of a normal and recurring nature considered necessary for a fair presentation have been included in the accompanying condensed consolidated financial statements. The results of operations for the interim period are not necessarily indicative of the results that will be realized for the entire fiscal year. These condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements and accompanying notes thereto included in the Company’s 2023 Annual Report filed on Form 10-K with the SEC on March 7, 2024.
Use of Estimates	Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company ’s financial statements and accompanying notes. Significant management estimates that affect the reported amounts of assets and liabilities include stock-based compensation, accruals for clinical trials and deferred tax assets. While we believe that the estimates and assumptions used in preparation of our condensed consolidated financial statements based on our knowledge of current events and actions that we may undertake in the future are appropriate, actual results could differ from those estimates, and any such differences may be material. As of March 31, 2024, the Company’s significant accounting policies are consistent with those discussed in Note 2 - “ Summary of Significant Accounting Policies and Recent Accounting Pronouncements ” of its consolidated financial statements included in the Company’s 2023
Recent Accounting Pronouncements	Recent Accounting Pronouncements In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740)—Improvements to Income Tax Disclosures . This ASU requires that reporting entities disclose specific categories in the effective tax rate reconciliation as well as information about income taxes paid. The authoritative guidance is effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the effect of this new guidance on its consolidated financial statements.
Fair Value	Fair Value The fair values of the Company’s financial instruments are recorded using a hierarchical disclosure framework based upon the level of subjectivity of the inputs used in measuring assets and liabilities. The three levels are described below: • Level 1: Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date . • Level 2: Inputs other than Level 1 that are directly or indirectly observable, such as quoted prices for similar assets or liabilities and quoted prices in less active markets. • Level 3: Inputs are unobservable for the asset or liability and are developed based on the best information available in the circumstances, which might include the Company’s own data.

Financial Instruments (Tables)

Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2024
Fair Value Disclosures [Abstract]
Summarizes the Valuation of the Company’s Financial Instruments	The following summarizes the valuation of the Company’s financial instruments (in thousands). The tables do not include either cash on hand or assets and liabilities that are measured at historical cost or any basis other than fair value. As of March 31, 2024 Level 1 Level 2 Total Cash equivalents: Money market funds $ 22,553 $ — $ 22,553 Total cash equivalents $ 22,553 $ — $ 22,553 As of December 31, 2023 Level 1 Level 2 Total Cash equivalents: Money market funds $ 34,741 $ — $ 34,741 Total cash equivalents $ 34,741 $ — $ 34,741 Short-term investments: U.S. government and agency securities — 999 999 Total short-term investments $ — $ 999 $ 999 Total $ 34,741 $ 999 $ 35,740 The following table summarizes the Company's available-for-sale securities by security type: As of March 31, 2024 Amortized Cost Unrealized Losses Fair Value Cash equivalents: Money market funds $ 22,553 $ — $ 22,553 Total cash equivalents $ 22,553 $ — $ 22,553 As of December 31, 2023 Amortized Cost Unrealized Losses Fair Value Cash equivalents: Money market funds $ 34,741 $ — $ 34,741 Total cash equivalents $ 34,741 $ — $ 34,741 Short-term investments: U.S. government and agency securities 999 — 999 Total short-term investments $ 999 $ — $ 999 Total $ 35,740 $ — $ 35,740

Accrued Expenses (Tables)

Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2024
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses are comprised of the following (in thousands): March 31, 2024 December 31, 2023 Compensation and related benefits $ 1,752 $ 3,472 Clinical and contract manufacturing expenses 1,388 1,790 Other 412 596 Total accrued expenses $ 3,552 $ 5,858

Stock-Based Compensation and _2

Stock-Based Compensation and Employee Benefit Plans (Tables)	3 Months Ended
	Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]
Schedule of Share-based Compensation Expense	Stock-based compensation expenses included in the Company’s condensed consolidated statements of operations for the three months ended March 31, 2024 and 2023 were (in thousands): Three Months Ended March 31, 2024 2023 Research and development $ 142 $ 157 General and administrative 438 429 Total $ 580 $ 586

Net Loss per Share of Common _2

Net Loss per Share of Common Stock (Tables)	3 Months Ended
	Mar. 31, 2024
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Net Loss per Share of Common Stock	The following table presents the computation of basic and diluted loss per share of common stock (in thousands, except share and per share data) and the number of unexercised stock options and restricted stock units, which are common stock equivalents, that have been excluded from the diluted net loss calculation as their effect would have been anti-dilutive for all periods presented. Three Months Ended March 31, 2024 2023 Net loss $ (10,441) $ (7,346) Weighted-average shares outstanding - Basic and diluted 8,104,905 8,239,941 Net loss per share - Basic and diluted $ (1.29) $ (0.89) Anti-dilutive stock options 1,553,359 1,490,884 Anti-dilutive restricted stock units 55,901 76,165 Total anti-dilutive common stock equivalents excluded 1,609,260 1,567,049

Description of Business (Detail

Description of Business (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and cash equivalents	$ 23,179	$ 35,078
Accumulated deficit	$ (171,958)	$ (161,517)

License and Asset Purchase Ag_2

License and Asset Purchase Agreements (Details) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2018	Mar. 18, 2020	Nov. 30, 2014
Asset Acquisition [Line Items]
Payments for royalties	$ 0.1	$ 0.4
Merck | Royalty revenue
Asset Acquisition [Line Items]
Grant revenue	0.2	$ 0.7
License and Collaborative Arrangement | Merck
Asset Acquisition [Line Items]
Collaborative arrangement development milestone payments	14
Collaborative arrangement second indication development milestone payments	8.5
Collaborative arrangement tiered sales milestone payments	80
Net product sales milestone	$ 1,000
Value of PRV company is entitled to					60%
Value of PRV liability				40%
License and Collaborative Arrangement | Merck | Minimum
Asset Acquisition [Line Items]
Royalty obligation percent of annual product net sales	10%
License and Collaborative Arrangement | Merck | Maximum
Asset Acquisition [Line Items]
Royalty obligation percent of annual product net sales	12%
Ammonett
Asset Acquisition [Line Items]
Upfront payments			$ 3.5
Acquisition development milestone payments			17
Acquisition specific milestone payments	$ 2		14
Acquisition sales milestone payments			$ 55

Financial Instruments - Summary

Financial Instruments - Summary of the Valuation of the Company’s Financial Instruments (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total cash equivalents	$ 22,553	$ 34,741
Short-term investments:		999
Total		35,740
U.S. government and agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments:		999
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total cash equivalents	22,553	34,741
Short-term investments:		0
Total		34,741
Level 1 | U.S. government and agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments:		0
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total cash equivalents	0	0
Short-term investments:		999
Total		999
Level 2 | U.S. government and agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments:		999
Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total cash equivalents	22,553	34,741
Money market funds | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total cash equivalents	22,553	34,741
Money market funds | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total cash equivalents	$ 0	$ 0

Financial Instruments - Schedul

Financial Instruments - Schedule of Available for Sale by Security Type (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost		$ 35,740
Unrealized Losses		0
Fair Value		35,740
Cash Equivalents
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	$ 22,553	34,741
Unrealized Losses	0	0
Fair Value	22,553	34,741
Cash Equivalents | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	22,553	34,741
Unrealized Losses	0	0
Fair Value	$ 22,553	34,741
Short-Term Investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost		999
Unrealized Losses		0
Fair Value		999
Short-Term Investments | U.S. government and agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost		999
Unrealized Losses		0
Fair Value		$ 999

Accrued Expenses - Summary (Det

Accrued Expenses - Summary (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Accrued expenses
Compensation and related benefits	$ 1,752	$ 3,472
Clinical and contract manufacturing expenses	1,388	1,790
Other	412	596
Total accrued expenses	$ 3,552	$ 5,858

Stock-Based Compensation and _3

Stock-Based Compensation and Employee Benefit Plans - Narrative (Details) - USD ($) $ in Millions		3 Months Ended
	May 09, 2019	Mar. 31, 2024
Share-based Compensation Arrangement by Share-based Payment Award
Unrecognized compensation cost		$ 2.3
Weighted average vesting period for non-vested option awards (in years)		2 years 1 month 6 days
2009 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award
Plan term		10 years
Evergreen increase (percent)	3%
Number of shares remained available for issuance (in shares)		791,018
2010 Non-Employee Directors' Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award
Number of shares remained available for issuance (in shares)		5,624
2010 Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award
Number of shares remained available for issuance (in shares)		35,946
2010 Employee Stock Purchase Plan | ESPP
Share-based Compensation Arrangement by Share-based Payment Award
Increase in shares reserved for future issuance (in shares)		60,000

Stock-Based Compensation and _4

Stock-Based Compensation and Employee Benefit Plans - Allocated Share-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expense	$ 580	$ 586
Research and development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expense	142	157
General and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expense	$ 438	$ 429

Long-Term Debt and Conversion_2

Long-Term Debt and Conversion to Royalty Obligation (Details) - IDED - Loans payable - USD ($) $ in Millions	Mar. 31, 2024	Mar. 31, 2005
Debt Instrument [Line Items]
Loan available balance		$ 6
Outstanding balance	$ 6

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Income tax benefit	$ 0	$ 0

Net Loss per Share of Common _3

Net Loss per Share of Common Stock - Net Loss Per Share Computation (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Net loss	$ (10,441)	$ (7,346)
Weighted-average shares outstanding - Basic (in shares)	8,104,905	8,239,941
Weighted-average shares outstanding - Diluted (in shares)	8,104,905	8,239,941
Net loss per share - Basic (in dollars per share)	$ (1.29)	$ (0.89)
Net loss per share - Diluted (in dollars per share)	$ (1.29)	$ (0.89)
Antidilutive securities (in shares)	1,609,260	1,567,049
Stock Option
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities (in shares)	1,553,359	1,490,884
Restricted Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities (in shares)	55,901	76,165